---
title: "IDEAYA Biosciences grants 260,200 inducement stock options at $36.4 per share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294493218.md"
description: "IDEAYA Biosciences granted 260,200 inducement stock options to 14 new employees on July 30, 2026. The options carry an exercise price of $36.4 per share, aligning with the Nasdaq closing price. These awards have a 10-year term, with vesting scheduled at 25% after one year and monthly thereafter over the next three years."
datetime: "2026-07-31T10:00:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294493218.md)
  - [en](https://longbridge.com/en/news/294493218.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294493218.md)
generator: "portal-rs"
---

# IDEAYA Biosciences grants 260,200 inducement stock options at $36.4 per share

-   IDEAYA Biosciences issued inducement stock options covering 260,200 shares to 14 newly hired employees on July 30, 2026. \* Options carry an exercise price of USD 36.4 per share, matching the stock’s Nasdaq close on the grant date. \* Awards run for 10 years; vesting is 25% after one year, then monthly over the next three years. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607310600PR\_NEWS\_USPR\_\_\_\_\_FL16456) on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md)

## Related News & Research

- [IDEAYA Biosciences (IDYA) Doses First Patient In Phase 3 Uveal Melanoma Trial](https://longbridge.com/en/news/298778032.md)
- [IDYA: Darovasertib NDA nears completion as pipeline expands with DLL3 ADC, PRMT5, and Roche collaborations](https://longbridge.com/en/news/298488281.md)
- [Septerna grants new CMO Rajiv Patni option for 275,000 shares at $37.37 each](https://longbridge.com/en/news/298637901.md)
- [UiPath survey flags orchestration as key to scaling enterprise agentic AI deployments](https://longbridge.com/en/news/298458536.md)
- [InMed FY26 net loss widens to US$12.9 million; discontinued-ops sales drop 36% to US$3.2 million](https://longbridge.com/en/news/298501424.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**